Business
Cue Biopharma Welcomes Tamar Howson to its Board of Directors
Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development
About this update from Cue Biopharma, Inc.
[{"type":"text","content":"Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development\n CAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the appointment of Tamar Howson to its board of directors. Ms. Howson brings broad corporate and business development experience to the board, having held executive leadership positions in several global biopharmaceutical and pharmaceutical companies, as well as her many board appointments. “We are very pleased to welcome Tamar Howson to the Cue Biopharma board of directors,” said Frank Morich, M.D., Ph.D., chairman of the board. “Tamar brings a wealth of experience and knowledge in corporate, as well as business development and we believe she will complement the board with her core strengths and capabilities.” “I am thrilled to join Cue Biopharma’s board of directors and look forward to working with the board and collaborating with the Company’s leadership team to further develop and advance their key corporate development initiatives in becoming a leader in targeted immunotherapy,” commented Ms. Howson. Daniel Passeri, chief executive officer of Cue Biopharma said, “We are delighted to have Tamar join our board of directors. Tamar’s corporate and business development expertise within the pharmaceutical and biotechnology industries will be a significant resource to Cue Biopharma’s management team, as well as the board, as we continue to develop strategically and execute our corporate development objectives.” About Tamar Howson Ms. Howson is a highly experienced business development executive and consultant with more than 30 years of service in the pharmaceutical and biotechnology industries. Ms. Howson currently serves on the board of directors of MEI Pharma, Inc. and Immunic, Inc. Between 2009 and 2019 she has also served on the boards of various life sciences companies including Actavis PLC, Aradigm Corporation, ContraVir Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., Enzymotec PLC, Idenix Pharmaceuticals, Inc., OXiGENE, Inc., Organovo Holdings Inc. and Scientus Pharma, Inc. From 2009 to 2011, Ms. Howson serv...